Edgewise Therapeutics, Inc.
EWTX
Rang în acțiuni
#3979
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Preț acțiune
$38.12
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$4.10B
Schimbare (1 zi)
2.50%
Schimbare (1 an)
147.69%
Țară
US
Tranzacționează Edgewise Therapeutics, Inc. (EWTX)
Categorie
Healthcare
Raport P/S pentru Edgewise Therapeutics, Inc. (EWTX)
Raport P/S la data de October 2026 TTM: 0.00
Conform celor mai recente rapoarte financiare și prețului acțiunilor Edgewise Therapeutics, Inc., raportul P/S actual (TTM) este 0.00. La sfârșitul anului 2023, compania avea un P/S de 0.00.
Istoricul raportului P/S pentru Edgewise Therapeutics, Inc. din 2019 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
